The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2022 | The role of frontline chemoimmunotherapy in the era of novel agents in CLL
Michel van Gelder, MD, PhD, Maastricht University, Maastricht, Netherlands, comments on the relevance of chemoimmunotherapy in the frontline treatment of patients with chronic lymphocytic leukemia (CLL) in the era of novel agents. Dr van Gelder argues that the benefits of frontline targeted therapy in the long term are not well-established. In addition, a shorter treatment with chemoimmunotherapy may lead to fewer adverse events than a longer treatment with novel agents. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
